Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514831 | 1.00 | MEN1 (0.53) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21177415 | 1.00 | MEN1 (0.53) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21177419 | 0.85 | HPGD (0.50) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21177416 | 0.85 | HPGD (0.50) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30514822 | 0.85 | HPGD (0.50) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30514851 | 0.81 | DRD2 (0.57) | MEN1KMT2AALDH1A1HPGDHCRTR1 | |
| SCHEMBL21177380 | 0.81 | DRD2 (0.57) | MEN1KMT2AALDH1A1HPGDHCRTR1 | |
| SCHEMBL21177378 | 0.81 | DRD2 (0.57) | MEN1KMT2AALDH1A1HPGDHCRTR1 | |
| SCHEMBL4480837 | 0.81 | TP53 (0.60) | MEN1KMT2ARAB9AALDH1A1HPGD | |
| SCHEMBL4480840 | 0.81 | TP53 (0.60) | MEN1KMT2ARAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| CN-111868063-B | PI4KIII beta inhibitors | 葛兰素史克知识产权开发有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3740489-A1 | PI4KIIIBETA INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | MEN1 3572/4885KMT2A 1239/4885RAB9A 758/4885 |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | PI4K2A, PI4K2B, PI4KA | MEN1 4344/4885KMT2A 1679/4885RAB9A 1214/4885 |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | MEN1 3563/4885KMT2A 1237/4885RAB9A 797/4885 |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | PI4KB, PI4K2B, PI4K2A | MEN1 3563/4885KMT2A 1237/4885RAB9A 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.